Trial Profile
A Phase II Multicenter Study of Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2017
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 20 Dec 2016 Status changed from active, no longer recruiting to completed.
- 07 Jan 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
- 07 Jan 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov record.